|Bid||68.01 x 1100|
|Ask||68.85 x 1300|
|Day's range||67.89 - 69.37|
|52-week range||61.39 - 74.12|
|Beta (5Y monthly)||0.36|
|PE ratio (TTM)||11.78|
|Earnings date||01 Feb 2022|
|Forward dividend & yield||2.84 (4.15%)|
|Ex-dividend date||14 Dec 2021|
|1y target est||77.00|
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences (GILD) closed the most recent trading day at $68.57, moving +0.09% from the previous trading session.
Gilead (GILD) gets FDA approval for label expansion of Veklury for the treatment of non-hospitalized patients at high risk for COVID-19 disease progression.